Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Delpazolid as Add-on Therapy in Refractory Mycobacterium Abscessus Complex Pulmonary Disease
NCT06004037Phase 2Completed
- Sponsor
- LigaChem Biosciences
- Start
- Jan 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of delpazolid in Mycobacterium abscessus complex pulmonary disease, sponsored by LigaChem Biosciences. Started Jan 2024; status: completed.
02
Drugs
delpazolid
03
Conditions
Mycobacterium abscessus complex pulmonary disease
Beyond the preview
Go deeper on NCT06004037.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06004037.